Study on Prostate Cancer Mortality: Prostatectomy vs. Observation

Overview of Prostate Cancer

Prostate cancer is among the most frequently diagnosed cancers in men, characterized by its slower progression compared to other malignancies. Recently, the incidence of prostate cancer has been on the rise, likely due to increased screening for prostate-specific antigen (PSA) levels. PSA is produced by the prostate gland, and elevated levels can indicate prostate infection, inflammation, or cancer.

Treatment Options for Prostate Cancer

Patients diagnosed with prostate cancer have access to various treatment modalities, including surgery, radiation therapy, and hormonal therapy. Active surveillance involves closely monitoring the patient without immediate intervention, while radical prostatectomy refers to the surgical removal of the prostate gland. Treatment options and prognosis are influenced by factors such as the cancer stage, patient age, and overall health.

The PIVOT Trial

A recent article published in the New England Journal of Medicine detailed the findings of the Prostate Cancer Intervention versus Observation Trial (PIVOT). Initiated during the early days of PSA testing, the trial involved 731 men with localized prostate cancer. From November 1994 to January 2002, 364 men underwent radical prostatectomy, while 367 were placed under active surveillance, with follow-up extending to August 2014. The participants had a mean age of 67 years and a median PSA level of 7.8 ng/mL.

The primary objective of the study was to analyze all-cause mortality, with prostate cancer mortality as a secondary outcome. Researchers also examined disease progression, additional treatments, adverse events, and patient-reported outcomes related to urinary incontinence, sexual dysfunction, physical discomfort, and functional limitations.

Patient tumor risk classification was determined at the study’s onset based on PSA levels, Gleason scores (which evaluate cancer cell appearance), and T stage (tumor size), categorizing them into low-risk, intermediate-risk, or high-risk groups.

Comparative Results: Prostatectomy vs. Observation

The follow-up period of approximately 12.7 years revealed that out of 731 men, 468 had died, with 69 (9.4%) of those deaths attributed to prostate cancer-related causes. The prostatectomy group demonstrated an overall survival rate of 13 years, compared to 12.4 years for the observation group, with no significant difference in mortality during the follow-up.

Analysis across different risk categories showed no substantial mortality differences between the two groups. However, men classified with intermediate-risk tumors exhibited lower all-cause mortality in the prostatectomy group, with cumulative prostate cancer mortality at 7.4% for surgery patients versus 11.4% for those under surveillance. Additionally, fewer patients in the prostatectomy group experienced disease progression or required further treatment. Nonetheless, reports of physical discomfort, urinary incontinence, and erectile dysfunction were more prevalent among those who underwent surgery.

Clinical Implications of the PIVOT Findings

The nearly two-decade follow-up in the PIVOT trial indicated no significant overall or cancer-specific survival advantages conferred by radical prostatectomy compared to observation. These findings were largely influenced by the subset of patients with low-risk prostate cancer, who generally demonstrated good prognoses without treatment.

The trial suggests that men with high-risk prostate cancer may experience improved survival rates post-surgery. Conversely, those with intermediate-risk cancer showed lower all-cause mortality without a corresponding decrease in prostate cancer-specific mortality. Furthermore, surgery did not enhance survival rates in high-risk cancer patients, although disease progression was less frequently observed in the surgical cohort.

It is essential to recognize that factors such as urinary incontinence, vitality, and sexual function, associated with radical prostatectomy, significantly impact patient satisfaction.

Conclusion

In summary, findings from the PIVOT trial suggest that radical prostatectomy does not significantly lower mortality rates in patients with clinically localized prostate cancer. Surgery was associated with a higher frequency of adverse events compared to observation, while treatment for disease progression was less necessary in those who underwent surgery. Caution is advised in interpreting these results for various patient subgroups.

Written by Preeti Paul, MS Biochemistry
Reference: Timothy J. Wilt et al., Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 2017;377:132-42.